Myelodysplastic Syndrome Treatment Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-06　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 2.99 Bn
2033 年預估規模: USD 4.63 Bn
年複合成長率 CAGR: 6.4%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-02-06頁數 152報告編號 CMI775

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Myelodysplastic Syndrome Treatment Market, By Drug (Lenalidomide, Decitabine, Azacitidine, Phase 3 Drugs), By Route Of Administration (Injection, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The different types of myelodysplastic syndromes are diagnosed based on certain changes in the blood cells and bone marrow. Myelodysplastic syndromes (MDS) are a type of rare blood cancers where don't have enough healthy blood cells. It is also known as myelodysplasia. There are several different types of MDS. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and have problems making new blood cells. Several of the blood cells formed by these bone marrow cells are defective. Defective cells often die earlier than normal cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in Myelodysplastic syndromes is a shortage of red blood cells (anemia). Therapy-related MDS is a subtype of Myelodysplastic syndromes. It is caused by treatment with chemotherapy or radiation therapy for a previous cancer. In the U.S., the number of new diagnoses of Myelodysplastic syndromes and therapy-related Myelodysplastic syndromes are both rising. This is because older people make up a growing segment of the population and people now live longer after treatment for cancer. Market Dynamics Increasing launch and approval of Azacitidine in key regions namely North America, Latin America, Europe, Asia Pacific, and Africa etc. is expected to drive growth of Azacitidine segment of the myelodysplastic syndrome treatment market over the forecast period. For instance, in February 2018, BeiGene, Ltd. Biotechnology Company announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation (Pharmaceutical Company). Key features of the study • This report provides an in-depth analysis of the global myelodysplastic syndrome (MDS) treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global myelodysplastic syndrome (MDS) treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myelodysplastic syndrome (MDS) treatment market Market Segmentation • Drug Insights (Revenue, USD Bn, 2026 - 2033) o Lenalidomide o Decitabine o Azacitidine o Phase 3 Drugs • Route of Administration Insights (Revenue, USD Bn, 2026 - 2033) o Injection o Oral • Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Bn, 2026 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  North Africa  Central Africa  South Africa • Key Players Insights o Celgene Corporation o Otsuka Pharmaceutical Co., Ltd. o Teva Pharmaceutical Industries Ltd. o Sun Pharmaceutical Industries Limited o Dr. Reddy's Laboratories Ltd. o Mylan NV o Cipla Limited o Acceleron Pharma, Inc. o Aprea Therapeutics o FibroGen Inc. o Onconova Therapeutics Inc. o Geron

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Overview o Report Description  Market Definition and Scope o Executive Summary  Global Myelodysplastic Syndrome Treatment Market, By Drug  Global Myelodysplastic Syndrome Treatment Market, By Route of Administration  Global Myelodysplastic Syndrome Treatment Market, By Distribution Channel  Global Myelodysplastic Syndrome Treatment Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trend 4. Global Myelodysplastic Syndrome Treatment Market, By Drug, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Lenalidomide  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Decitabine  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Azacitidine  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Phase 3 Drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) 5. Global Myelodysplastic Syndrome Treatment Market, By Route of Administration, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Injection  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Oral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) 6. Global Myelodysplastic Syndrome Treatment Market, By Distribution Channel, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) 7. Global Myelodysplastic Syndrome Treatment Market, By Region, 2020 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 8. Competitive Landscape o Celgene Corporation  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Otsuka Pharmaceutical Co., Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Teva Pharmaceutical Industries Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sun Pharmaceutical Industries Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Dr. Reddy's Laboratories Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Mylan NV  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Cipla Limited  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Acceleron Pharma, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Aprea Therapeutics  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o FibroGen Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Onconova Therapeutics Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Geron  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 9. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 10. References and Research Methodology o References o Research Methodology o About us

提及公司

Celgene CorporationOtsuka Pharmaceutical Co., Ltd.Teva Pharmaceutical Industries Ltd.Sun Pharmaceutical Industries LimitedDr. Reddy's Laboratories Ltd.Mylan NVCipla LimitedAcceleron Pharma, Inc.Aprea TherapeuticsFibroGen Inc.Onconova Therapeutics Inc.Geron

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們